Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 24:13:1305322.
doi: 10.3389/fonc.2023.1305322. eCollection 2023.

Comparing real-world outcomes of total neoadjuvant treatment and CRT at a tertiary medical center

Rim Turfa  1 , Tala Alawabdeh  1 , Ayman Naser  2 , Yazan Alamro  3 , Moath Albliwi  3 , Sama Almasri  3 , Abdullah Al Qazakzeh  3 , Mohammad Abu Shattal  4 , Ali Dabous  2 , Rula Amarin  1
Affiliations

Comparing real-world outcomes of total neoadjuvant treatment and CRT at a tertiary medical center

Rim Turfa et al. Front Oncol. .

Abstract

Introduction: For years, standard treatment for locally advanced rectal cancer (LARC) has included neoadjuvant chemoradiotherapy (CRT), followed by surgery and adjuvant chemotherapy. Although CRT has helped reduce local recurrence rates, it hasn't consistently improved overall survival. Recent trials have unveiled a different approach called total neoadjuvant treatment (TNT), involving pre-surgery radiotherapy followed by chemotherapy (CAPOX/FOLFOX). TNT shows promise with improved treatment response and lower distant metastasis rates without compromising local control. Consequently, many healthcare institutions have adopted TNT as their preferred neoadjuvant treatment. This study, conducted at a tertiary center, compares the real-world outcomes of both CRT and TNT protocols.

Methods: In this retrospective study of 390 patients treated between 2015 and 2021, aged 18 or older with LARC and tumors within 12 cm of the anal verge, we compared treatment outcomes. We assessed factors like pathological complete remission (pCR), three-year event-free survival (EFS), and overall survival (OS) between the two treatment groups using the Chi-squared test.

Results: Out of the 390 eligible patients, 256 underwent CRT, while 84 received TNT. Surgery was performed on 215 (84%) patients in the CRT group, compared to 55 (65.5%) in the TNT group. Notably, 33 (12.8%) achieved pCR in the CRT group, whereas 23 (27.7%) achieved pCR in the TNT group (P <.001). Regardless of whether surgery was performed or not, the TNT group exhibited lower recurrence rates (12.7% vs. 18.6% with surgery, 28.6% vs. 45% without surgery). The 3-year EFS rate was 80% in the CRT group and 90% in the TNT group (P = .05). Additionally, the 3-year OS rates favored the TNT group, standing at 96.4% compared to 84.4% in the CRT group (P = .005).

Conclusion: Our findings indicate that patients who underwent TNT demonstrated a higher likelihood of achieving pCR and experienced lower recurrence rates compared to those in the CRT group. Additionally, the TNT group exhibited superior 3-year EFS and OS. It is important to note, however, that a longer follow-up period is required to further validate these results.

Keywords: chemoradiotherapy; complete remission; locally advanced rectal cancer; recurrence; total neoadjuvant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Three-year event-Free Survival (EFS) rate was 80% in the CRT group compared to 90% in the TNT group.
Figure 2
Figure 2
Three-year Overall Survival (OS) rates were 84.4% in the CRT group and 96.4% in the TNT group.
See this image and copyright information in PMC

References

    1. Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: An international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol (2008) 14(21):3281. doi: 10.3748/wjg.14.3281 - DOI - PMC - PubMed
    1. Engstrom PF, Benson AB, Saltz L. National Comprehensive Cancer Network. Colon cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2003) 1(1):40–53. doi: 10.6004/jnccn.2009.0056 - DOI - PMC - PubMed
    1. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med (2001) 345(9):638–46. doi: 10.1056/NEJMoa010580 - DOI - PubMed
    1. Van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EMK, Putter H, Wiggers T, et al. . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 12(6):575–82. doi: 10.1016/S1470-2045(11)70097-3 - DOI - PubMed
    1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 355(11):1114–23. doi: 10.1056/NEJMoa060829 Erratum in: N Engl J Med (2007) 357(7):728. - DOI - PubMed